A Review on the Dual Role of SOCS3 in Cancer | ||
| Research in Oncology | ||
| Article 1, Volume 18, Issue 1, June 2022, Pages 1-9 PDF (249.46 K) | ||
| Document Type: Review articles | ||
| DOI: 10.21608/resoncol.2022.114548.1159 | ||
| Authors | ||
| Rajdeep Chakraborty* 1; Charbel Darido2, 3; Aziz A. A. Alnakli1; Honghua Hu1; Karen Vickery1 | ||
| 1Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia | ||
| 2Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia | ||
| 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3000, Australia | ||
| Abstract | ||
| Background: Aberrant proliferation is a hallmark of cancer. Cellular proliferation mechanisms and various cytokines contribute to the progression of cancer. The tumor suppressor protein Suppressor of Cytokine Signalling 3 (SOCS3), which acts via the JAK/STAT pathway, have a role in the progression of cancer. Aim: To explore the role of SOCS3 in all the hallmarks of cancer. To exhibit SOCS3 action on proliferation pathways and immune aspect affecting cancer progression. Methods: The PubMed database was searched using the keywords proliferation, SOCS3, JAK/STAT, interleukins, and tumor suppressor. Articles relevant to SOCS3 were considered for this review. Results: In this review, we have illustrated the dual action of SOCS3, which inhibits various proliferative mechanisms and affects certain interleukins that counterbalance the progression of cancer. In addition, SOCS3 affects all the hallmarks of cancer. Conclusion: We hope that this review will stimulate further investigation of SOCS3, which has the potential to become a new target for the pharmacological treatment of various cancers in the future. | ||
| Keywords | ||
| Cancer; SOCS3; JAK/STAT; Interleukins; Proliferation | ||
|
Statistics Article View: 616 PDF Download: 629 |
||
